News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
友芝友生物(02496.HK)M701治療惡性腹水新藥上市申請獲受理
友芝友生物-B(02496.HK)公布，自主研發的雙特異性抗體藥物M701治療晚期上皮性惡性腫瘤導致的惡性腹水的新藥上市申請已獲得國家藥監局正式受理。M701正在中國開展針對惡性腹水及惡性胸水的多項不同階段的臨床試驗，包括一項針對上皮性實體瘤引發的惡性腹水的關鍵III期臨床試驗，其新藥上市申請已獲國家藥監局的正式受理，以及一項針對非小細胞肺癌引發的惡性胸水的...
Reset
Send
The window will close in 5 seconds
友芝友生物(02496.HK)M701治療惡性腹水新藥上市申請獲受理
Close
Recommend
3
Positive
1
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

友芝友生物-B(02496.HK)  0.000 (0.000%)   公布，自主研發的雙特異性抗體藥物M701治療晚期上皮性惡性腫瘤導致的惡性腹水的新藥上市申請已獲得國家藥監局正式受理。

M701正在中國開展針對惡性腹水及惡性胸水的多項不同階段的臨床試驗，包括一項針對上皮性實體瘤引發的惡性腹水的關鍵III期臨床試驗，其新藥上市申請已獲國家藥監局的正式受理，以及一項針對非小細胞肺癌引發的惡性胸水的II期臨床試驗，目前已完成受試者入組。(ha/da)(HK stocks quote is delayed for at least 15 mins.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.